CNX Therapeutics Ltd.

CNX Therapeutics is a Specialty, European Pharmaceutical Company dedicated to the treatment of CNS disorders. In 2021 Inflexion Private Equity Partners LLP a leading global investment firm, acquired the European subsidiary (now known as CNX Therapeutics) of a leading global CNS focused pharmaceutical company. The goal of CNX Therapeutics is to build a successful European business which will commercialise CNS treatment options and become a specialist in this therapy area. We currently commercialise and distribute (either directly or via our trusted partners) LATUDA® (lurasidone) in Europe, and seek to capitalise on this foundation by building a portfolio of CNS assets. We will do this by: - Successfully leveraging our footprint and capabilities across Europe and beyond. - Being a trusted partner of choice for the out-licensing, and divestment of pharmaceutical products. - Striving to continually develop our people harnessing key skills and leveraging cross functional collaboration. CNX Therapeutics has designed and successfully executed a relatively unique 'Hub & Spoke' business model (since 2014) which is now operating smoothly across 7 countries, and will continue to expand as the company grows. The 'hub' or European office of this business model is in London. We collaborate successfully with commercial alliance partners in Europe, Russia, and Middle East, N Africa. CNX Therapeutics will achieve its goals by embracing its core values: Work as one team, Operate with high standards, Deliver on our commitments, Focus on bespoke solutions, Communicate openly and transparently and Empower our people.